Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
About this item
Full title
Author / Creator
Publisher
United States: American Association for the Advancement of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Association for the Advancement of Science
Subjects
More information
Scope and Contents
Contents
CD47 is an antiphagocytic signal that cancer cells employ to inhibit macrophage-mediated destruction. Here, we modified the binding domain of human SIRPα, the receptor for CD47, for use as a CD47 antagonist. We engineered high-affinity SIRPα variants with about a 50,000-fold increased affinity for human CD47 relative to wild-type SIRPα. As high-aff...
Alternative Titles
Full title
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2000355316
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2000355316
Other Identifiers
ISSN
0036-8075
E-ISSN
1095-9203
DOI
10.1126/science.1238856
